ChemGenex's Omapro Faces Scaled Back Efficacy Claims After Trial Shortcomings
This article was originally published in The Pink Sheet Daily
Executive Summary
Briefing documents for the advisory committee, now delayed by snow, show that many enrollees lacked a confirmed Bcr-Abl T315I mutation.